Networks
Depend on aHUS Source to get reliable information about atypical hemolytic uremic syndrome (aHUS), a chronic, life-threatening disease.
This page is to promote the awareness of autoimmune hepatitis
The Albert Einstein College of Medicine is one of the nation’s premier institutions for medical education, basic research and clinical investigation. It is home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students attending the Sue Golding Graduate Division —including 125 in the combined M.D./Ph.D. programs — and...
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins...
Alexion Pharmaceuticals is a global biopharmaceutical company that produces Soliris® (eculizumab), a first-in-class terminal complement inhibitor discovered, developed and marketed exclusively by Alexion. In March 2007, the U.S. Food and Drug Administration (FDA) approved Soliris as the first treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH).